Mumbai, Aug. 9 -- The approval reinforces Shilpa Medicare's commitment to addressing unmet medical needs in hepatology through innovation and evidence-based solutions.

This approval will allow Shilpa to become the first company in the World to launch this novel product in any part of the World for NAFLD.

NorUDCA is the first-in-class treatment for non-alcoholic fatty liver disease (NAFLD) in India, addressing a significant unmet medical need.

NAFLD is currently the most prevalent liver condition globally, affecting about 25% of the world's population (approximately 1.2 billion people) and impacting an estimated 188 million individuals in India alone.

If not managed early, NAFLD may progress to non-alcoholic steatohepatitis (NASH) and ...